Moreover, BET bromodomain inhibition can suppress GVHD through NF-κB regulation and decrease production of inflammatory cytokines such as IL-6, IL-12, TNF-α in DCs and IFN-γ, IL-2, IL-4 and IL-17 in activated T cells [79]. Here, IL2 is linked to graft versus host disease.